BRPI0818337A2 - quimioterápico cristalino - Google Patents

quimioterápico cristalino

Info

Publication number
BRPI0818337A2
BRPI0818337A2 BRPI0818337A BRPI0818337A BRPI0818337A2 BR PI0818337 A2 BRPI0818337 A2 BR PI0818337A2 BR PI0818337 A BRPI0818337 A BR PI0818337A BR PI0818337 A BRPI0818337 A BR PI0818337A BR PI0818337 A2 BRPI0818337 A2 BR PI0818337A2
Authority
BR
Brazil
Prior art keywords
chemotherapy
crystalline
crystalline chemotherapy
Prior art date
Application number
BRPI0818337A
Other languages
English (en)
Inventor
Chu-Kung Alexander
B Borchardt Thomas
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0818337A2 publication Critical patent/BRPI0818337A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0818337A 2007-10-19 2008-10-16 quimioterápico cristalino BRPI0818337A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19
PCT/US2008/080068 WO2009052231A1 (en) 2007-10-19 2008-10-16 Crystalline chemotherapeutic

Publications (1)

Publication Number Publication Date
BRPI0818337A2 true BRPI0818337A2 (pt) 2017-05-23

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818337A BRPI0818337A2 (pt) 2007-10-19 2008-10-16 quimioterápico cristalino

Country Status (19)

Country Link
US (1) US7772404B2 (pt)
EP (1) EP2195299A1 (pt)
JP (1) JP2011500708A (pt)
KR (1) KR20100084665A (pt)
CN (1) CN101827825B (pt)
AU (1) AU2008312534A1 (pt)
BR (1) BRPI0818337A2 (pt)
CA (1) CA2699356A1 (pt)
CO (1) CO6270221A2 (pt)
CR (1) CR11444A (pt)
DO (1) DOP2010000111A (pt)
EC (1) ECSP10010175A (pt)
GT (1) GT201000099A (pt)
MX (1) MX2010004287A (pt)
PA (1) PA8800401A1 (pt)
RU (1) RU2010119920A (pt)
UA (1) UA99490C2 (pt)
WO (1) WO2009052231A1 (pt)
ZA (1) ZA201002094B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PT1638941E (pt) * 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
RU2010119920A (ru) 2011-11-27
MX2010004287A (es) 2010-04-30
ZA201002094B (en) 2011-11-30
KR20100084665A (ko) 2010-07-27
AU2008312534A1 (en) 2009-04-23
EP2195299A1 (en) 2010-06-16
WO2009052231A1 (en) 2009-04-23
PA8800401A1 (es) 2009-05-15
CA2699356A1 (en) 2009-04-23
CR11444A (es) 2010-10-05
CN101827825B (zh) 2012-11-21
DOP2010000111A (es) 2010-07-15
US7772404B2 (en) 2010-08-10
CN101827825A (zh) 2010-09-08
UA99490C2 (en) 2012-08-27
US20090124816A1 (en) 2009-05-14
JP2011500708A (ja) 2011-01-06
ECSP10010175A (es) 2010-06-29
GT201000099A (es) 2012-03-26
CO6270221A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
BRPI0813500A2 (pt) Compostos antivirais
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
BRPI0811264A2 (pt) Compostos
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0809996A2 (pt) Compostos
BRPI0812994A2 (pt) Microbiocidas
BRPI0815181A2 (pt) Compostos
DE112008001216A5 (de) Magnetronplasmaanlage
DE112008003094A5 (de) Geomatte
DE112008003196A5 (de) Handpipettiergerät
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
BRPI0814613A2 (pt) Compostos
CU20090155A7 (es) Macrolidos
BRPI0818337A2 (pt) quimioterápico cristalino
BRPI0818334A2 (pt) quimioterapêutico cristalino

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]